How does Donanemab compare to other Alzheimer’s drugs? | Morning in America

Eli Lilly and Co. is seeking FDA approval for Donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease. Dr. Ian Smith weighs out the pros and cons of this drug’s ability to slow Alzheimer’s. Watch #MorningInAmerica: #Alzheimers #FDA #Donanemab Start your day with “Morning in America,“ NewsNation’s live three-hour national morning newscast hosted by Adrienne Bankert. Weekdays starting at 7a/6C. #MorningInAmerica NewsNation is your source for fact-based, unbiased news for all America. More from NewsNation: Get our app: Find us on cable: How to watch on TV or streaming: